Prothena Q2 Revenue Drops 97%
Prothena ( NASDAQ:PRTA ) , a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker-than-expected performance, with GAAP EPS of -2.34 missing the analysts' estimate of -1.25 ...
Prothena ( PRTA ) Reports Q2 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics ( PTCT ) Surges 11.2%: Is This an Indication of Further Gains?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Earnings Preview: Rhythm Pharmaceuticals, Inc. ( RYTM ) Q2 Earnings Expected to Decline
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Basel, 16 June 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease.
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Churchill Downs ( NASDAQ:CHDN ) , DBV Technologies ( NASDAQ:DBVT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Ascendiant Capital raised Pro-Dex, Inc. PDEX price target from $54 to $56.
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Abeona Therapeutics ( NASDAQ:ABEO ) , Ascentage Pharma Group ( NASDAQ:AAPG )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 500 points on Tuesday. Shares of PDD Holdings Inc. PDD fell sharply in today's pre-market trading following weaker-than-expected first-quarter results.
Why Is Prothena Stock Trading Lower On Tuesday? - Prothena Corp ( NASDAQ:PRTA )
AFFIRM-AL trial enrolled 207 newly diagnosed AL amyloidosis patients, dosing birtamimab every 28 days. Primary endpoint not met: HR=0.915, p=0.7680; secondary endpoints also missed, triggering program shutdown. Get stock picks, daily rankings, and pro-level trading tools in one powerful ...
US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert - Apple ( NASDAQ:AAPL ) , AutoZone ( NYSE:AZO )
U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of major benchmark indices were trading higher in premarket. The markets were closed on Monday in observance of Memorial Day holiday, affecting trading activity in the exchanges, including the New York Stock ...
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - RxSight ( NASDAQ:RXST ) , Prothena Corp ( NASDAQ:PRTA )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Prothena ( PRTA ) Reports Q1 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -21.74% and 86.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Roche presents novel therapeutic and diagnostic advancements in Alzheimer's at AD/PD 2025
Basel, 3 April 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria. Highlights included presentations from the ongoing trontinemab Phase Ib/IIa Brainshuttle™ ...
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Agilon Health ( NYSE:AGL ) , Maplebear ( NASDAQ:CART )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS cut Henry Schein, Inc. HSIC price target from $83 to $80. UBS analyst Kevin Caliendo maintained a ...
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit - Cognition Therapeutics ( NASDAQ:CGTX )
PITTSBURGH, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Cognition Therapeutics, Inc., ( the "Company" or "Cognition" ) CGTX, a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the ...
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
PITTSBURGH, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Cognition Therapeutics, Inc., ( the "Company" or "Cognition" ) ( NASDAQ: CGTX ) , a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will be co-hosting a precision medicine ...
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Prothena ( PRTA ) Reports Q4 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -5.88% and 85.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
Nurix Therapeutics, Inc. ( NRIX ) Reports Q4 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -11.94% and 22.55%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
The phase IIb PADOVA study, evaluating Roche's prasinezumab in people with early-stage Parkinson's disease, misses the primary endpoint.
Why Is Prothena Corp Stock Soaring Today? - Roche Holding ( OTC:RHHBY )
On Thursday, Prothena Corporation plc PRTA released results from the Phase 2b PADOVA study of prasinezumab in early-stage Parkinson's disease.
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday - Darden Restaurants ( NYSE:DRI ) , Accenture ( NYSE:ACN )
U.S. stocks were higher, with the Dow Jones index gaining over 150 points on Thursday. Shares of Accenture plc ACN rose sharply in today's session after the company reported better-than-expected first-quarter financial results and raised FY25 revenue growth outlook.
Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease
Basel, 19 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment.
Why Is Prothena ( PRTA ) Down 17.9% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Prothena ( PRTA ) Reports Q3 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Prothena ( PRTA ) Upgraded to Buy: What Does It Mean for the Stock?
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strength Seen in Prothena ( PRTA ) : Can Its 15.0% Jump Turn into More Strength?
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics ( NASDAQ:PRCT )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday. Shares of PROCEPT BioRobotics Corporation PRCT rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
Dow Dips 300 Points; Emcore Shares Spike Higher - Carnival ( NYSE:CCL )
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 300 points during on Monday. The Dow traded down 0.71% to 42,012.42 while the NASDAQ fell 0.52% to 18,026.03. The S&P 500 also fell, dropping, 0.45% to 5,712.53. Communication services shares fell by just ...
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher - Prime Medicine ( NASDAQ:PRME )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday. The Dow traded down 0.55% to 42,079.06 while the NASDAQ rose 0.14% to 18,144.66. The S&P 500 also fell, dropping, 0.14% to 5,730.18. Consumer staples shares jumped by 0.3% on ...
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
What Makes Prothena ( PRTA ) a New Buy Stock
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena ( PRTA ) Q2 Earnings Benefit From Collaboration Revenues
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Prothena ( PRTA ) Q2 Earnings and Revenues Beat Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 220.79% and 487.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as ...
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice ...
Merus N.V. ( MRUS ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
